Summary
Global Markets Direct’s, ‘Ragweed Allergy - Pipeline Review, H2 2016’, provides an overview of the Ragweed Allergy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy
- The report reviews pipeline therapeutics for Ragweed Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ragweed Allergy therapeutics and enlists all their major and minor projects
- The report assesses Ragweed Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ragweed Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
Immunomic Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ragweed Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Ragweed Allergy - Overview 7
Ragweed Allergy - Therapeutics under Development by Companies 8
Ragweed Allergy - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Unknown Stage Products 11
Ragweed Allergy - Products under Development by Companies 12
Ragweed Allergy - Companies Involved in Therapeutics Development 13
Anergis SA 13
Biomay AG 14
Circassia Pharmaceuticals Plc 15
Immunomic Therapeutics, Inc. 16
Ragweed Allergy - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
AllerR - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
BM-34 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Multi-LAMP-Vax - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
PL-101 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Ragweed Allergy - Dormant Projects 30
Ragweed Allergy - Discontinued Products 31
Ragweed Allergy - Product Development Milestones 32
Featured News & Press Releases 32
Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR 32
Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study 32
Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting 33
Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine 34
Mar 07, 2012: Circassia’s Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 35
Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37
List of Tables
Number of Products under Development for Ragweed Allergy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Comparative Analysis by Unknown Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Ragweed Allergy - Pipeline by Anergis SA, H2 2016 13
Ragweed Allergy - Pipeline by Biomay AG, H2 2016 14
Ragweed Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 15
Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Ragweed Allergy - Dormant Projects, H2 2016 30
Ragweed Allergy - Discontinued Products, H2 2016 31
List of Figures
Number of Products under Development for Ragweed Allergy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 21
